Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen

被引:108
作者
Desai, PB
Nallani, SC
Sane, RS
Moore, LB
Goodwin, BJ
Buckley, DJ
Buckley, AR
机构
[1] Univ Cincinnati, Med Ctr, Coll Pharm, Div Pharmaceut Sci, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Med Ctr, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA
[3] GlaxoSmithKline Inc, Dept High Throughput Biol, Res Triangle Pk, NC USA
[4] GlaxoSmithKline Inc, Dept Syst Res, Res Triangle Pk, NC USA
关键词
D O I
10.1124/dmd.30.5.608
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tamoxifen is a widely utilized antiestrogen in the treatment and chemoprevention of breast cancer. Clinical studies document that tamoxifen administration markedly enhances the systemic elimination of other drugs. Additionally, tamoxifen enhances its own clearance following repeated dosing. The mechanisms that underlie these clinically important events remain unresolved. Here, we report that tamoxifen and its metabolite 4-hydroxytamoxifen markedly induce cytochrome P450 3A4, a drug-metabolizing enzyme of central importance, in primary cultures of human hepatocytes. Tamoxifen and 4-hydroxytamoxifen (1-10 muM) significantly increased the CYP3A4 expression and activity (measured as the rate of testosterone 6beta-hydroxylation). Maximal induction was achieved at the 5 muM level. At this level, tamoxifen and 4-hydroxytamoxifen caused a 1.5- to 3.3-fold (mean, 2.1-fold) and 3.4- to 17-fold (mean, 7.5-fold) increase in the CYP3A4 activity, respectively. In comparison, rifampicin treatment resulted in a 6- to 16-fold (mean, 10.5-fold) increase. We also observed corresponding increase in the CYP3A4 immunoreactive protein and mRNA levels. Furthermore, tamoxifen and 4- hydroxytamoxifen efficaciously activated the human pregnane X receptor (hPXR; also known as the steroid xenobiotic receptor), a key regulator of CYP3A4 expression. The efficacy of tamoxifen and 4- hydroxytamoxifen relative to rifampicin for hPXR activation was similar to30 and 60%, respectively. Our results indicate that the mechanism of tamoxifen-mediated alteration in drug clearance pathways in humans may involve CYP3A4 induction by the parent drug and/or its metabolite. Furthermore, the CYP3A4 induction may be a result of hPXR activation. These findings have important implications for optimizing the use of tamoxifen and in the development of newer antiestrogens.
引用
收藏
页码:608 / 612
页数:5
相关论文
共 24 条
[1]   Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women:: a sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial [J].
Baum, M ;
Dowsett, M ;
Coibion, M ;
Bianco, AR ;
Cuzick, J ;
George, WD ;
Gray, J ;
Howell, A ;
Houghton, J ;
Williams, N ;
Sloane, J ;
Tobias, J ;
Buzdar, A ;
Anderson, MD ;
Jackson, I ;
Sahmoud, T ;
Gallagher, J ;
Webster, A ;
Gangji, D ;
Petrakova, K ;
Konopasek, B ;
Mares, P ;
Vodvarka, P ;
Alcazar, A ;
Campos, O ;
Maxwell, A ;
Goedhals ;
Hacking, D ;
Landers, G ;
Smith, L ;
Vorobiof, DA ;
Werner, ID ;
Blamey, R ;
Coleman, R ;
Grieve, RJ ;
Hickish, T ;
Howell, A ;
Nicholls, JC ;
Nicholson, S ;
Raymond, S ;
Salman, A ;
Blum, J ;
Clark, R ;
Lyss, A ;
Miletello, G ;
Sternberg, J ;
Forbes, J ;
Coibion, M ;
Nabholtz, JM ;
Guastalla, JP .
BRITISH JOURNAL OF CANCER, 2001, 85 (03) :317-324
[2]   Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction [J].
Bertilsson, G ;
Heidrich, J ;
Svensson, K ;
Åsman, M ;
Jendeberg, L ;
Sydow-Bäckman, M ;
Ohlsson, R ;
Postlind, H ;
Blomquist, P ;
Berkenstam, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) :12208-12213
[3]   SXR, a novel steroid and xenobiotic-sensing nuclear receptor [J].
Blumberg, B ;
Sabbagh, W ;
Juguilon, H ;
Bolado, J ;
van Meter, CM ;
Ono, ES ;
Evans, RM .
GENES & DEVELOPMENT, 1998, 12 (20) :3195-3205
[4]   GENOMIC SEQUENCING [J].
CHURCH, GM ;
GILBERT, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (07) :1991-1995
[5]  
Clarke R, 2001, PHARMACOL REV, V53, P25
[6]   Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes [J].
Crewe, HK ;
Ellis, SW ;
Lennard, MS ;
Tucker, GT .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :171-178
[7]  
Dowsett M, 1999, CLIN CANCER RES, V5, P2338
[8]   Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen [J].
Ducharme, J ;
Fried, K ;
Shenouda, G ;
LeylandJones, B ;
Wainer, IW .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (02) :189-193
[9]   TAMOXIFEN METABOLISM - PHARMACOKINETIC AND INVITRO STUDY [J].
ETIENNE, MC ;
MILANO, G ;
FISCHEL, JL ;
FRENAY, M ;
FRANCOIS, E ;
FORMENTO, JL ;
GIOANNI, J ;
NAMER, M .
BRITISH JOURNAL OF CANCER, 1989, 60 (01) :30-35
[10]   The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module [J].
Goodwin, B ;
Hodgson, E ;
Liddle, C .
MOLECULAR PHARMACOLOGY, 1999, 56 (06) :1329-1339